Clostridium innocuum: Microbiological and clinical characteristics of a potential emerging pathogen.
C. innocuum
Clinical microbiology
Clinical review
Emerging pathogen
Minireview
Journal
Anaerobe
ISSN: 1095-8274
Titre abrégé: Anaerobe
Pays: England
ID NLM: 9505216
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
11
06
2021
revised:
19
07
2021
accepted:
21
07
2021
pubmed:
1
8
2021
medline:
11
2
2022
entrez:
31
7
2021
Statut:
ppublish
Résumé
Clostridium innocuum is an anaerobic, gram-positive, spore-forming bacterium identified by Smith and King in 1962 after being isolated from a patient with an appendiceal abscess. Its name, C. innocuum, reflected its clinically "innocuous" nature based on observed lack of virulence in animal models of infection. Since that time, C. innocuum has been identified as both part of the normal intestinal flora and the cause of a rare, intrinsically vancomycin-resistant opportunistic infection in immunocompromised patients. More recently, reports from Taiwan suggest that C. innocuum, in addition to being a known extraintestinal pathogen, may also be a diarrheal pathogen that causes a C. difficile infection-like antibiotic-associated diarrheal illness. However, unanswered questions about the clinical relevance of C. innocuum remain. Here we review the microbiological and clinical characteristics of this emerging pathogen.
Identifiants
pubmed: 34332070
pii: S1075-9964(21)00101-3
doi: 10.1016/j.anaerobe.2021.102418
pmc: PMC9006188
mid: NIHMS1792569
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102418Subventions
Organisme : NIAID NIH HHS
ID : R21 AI144549
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007476
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Bacteriol. 1962 Apr;83:938-9
pubmed: 13914326
Microbiol Resour Announc. 2020 Jul 9;9(28):
pubmed: 32646898
BMC Infect Dis. 2010 Dec 30;10:363
pubmed: 21192802
Diagn Microbiol Infect Dis. 2001 Jul;40(3):103-6
pubmed: 11502376
Antimicrob Agents Chemother. 1986 Nov;30(5):798-801
pubmed: 3800358
Clin Infect Dis. 1995 Nov;21(5):1306-7
pubmed: 8589163
Clin Microbiol Infect. 2017 Aug;23(8):560-566
pubmed: 28254687
Clin Ther. 1987;10(1):107-25
pubmed: 3450391
J Clin Microbiol. 1998 Jun;36(6):1767-8
pubmed: 9620417
Anaerobe. 2014 Dec;30:24-6
pubmed: 25102472
J Bacteriol. 2004 Jun;186(11):3415-22
pubmed: 15150227
J Med Microbiol. 1995 Feb;42(2):78-82
pubmed: 7869351
Transpl Infect Dis. 2003 Dec;5(4):199-202
pubmed: 14987206
Antimicrob Agents Chemother. 1994 Nov;38(11):2599-604
pubmed: 7872754
Antimicrob Agents Chemother. 1976 Oct;10(4):736-52
pubmed: 984809
ScientificWorldJournal. 2009 Feb 28;9:144-8
pubmed: 19252754
Microbiology (Reading). 1994 Jan;140 ( Pt 1):105-11
pubmed: 8162181
Am J Med Sci. 2009 Jun;337(6):480-2
pubmed: 19525665
Surg Infect (Larchmt). 2009 Apr;10(2):111-8
pubmed: 19226203
Antimicrob Agents Chemother. 1999 Nov;43(11):2726-30
pubmed: 10543754
Clin Infect Dis. 1993 Jun;16 Suppl 4:S435-8
pubmed: 8324163
Biochim Biophys Acta. 1999 Nov 16;1472(3):550-4
pubmed: 10564769
J Clin Microbiol. 1995 Dec;33(12):3209-15
pubmed: 8586704
Anaerobe. 2004 Jun;10(3):171-7
pubmed: 16701515
Rev Esp Quimioter. 2019 Apr;32(2):192-193
pubmed: 30868838
J Infect Dis. 1975 May;131 Suppl:S81-5
pubmed: 805193
Presse Med. 1986 Dec 20;15(46):2279-81
pubmed: 2949268
Clin Microbiol Infect. 2018 Nov;24(11):1195-1199
pubmed: 29458157
Proc Natl Acad Sci U S A. 1985 Feb;82(4):1160-4
pubmed: 2579388
J Clin Pathol. 2005 Mar;58(3):301-7
pubmed: 15735165
Springerplus. 2015 Jul 29;4:385
pubmed: 26240783
Cell. 2020 Oct 29;183(3):666-683.e17
pubmed: 32991841